EconomyBig pharma races to hedge against patent expiries

Pharma firms completed more than $100 billion in biopharma buyouts during the first half of the year, seeking to replace about $400 billion in sales from top-selling medicines before their patents expire. Leah Bennett of Concurrent explains the trend.